Zymedyne Therapeutics is pleased to announce that a Mitacs Accelerate Industrial Postdoc has been awarded to Dr Ketul Patel to conduct structure-activity relationship studies and assess the molecular properties of Zymedyne’s lead molecules. Using organic synthesis and medicinal chemistry, Ketul’s work will also help develop new drugs with improved potency, specificity, and commercial potential. The Mitacs Accelerate Industrial Postdoc, together with the partnering company, provides up to three years of funding – valued at up to $60,000 per year. For more information, please visit: https://www.mitacs.ca/en/programs/accelerate/industrial-postdoc
Zymedyne Therapeutics awarded 1st place in the EntrepreNeuro Pitch Competition from Campus Alberta Neuroscience.
Zymedyne is pleased to announce that Co-founder Dr. Chris Bladen was awarded 1st place in the “EntrepreNeuro Pitch Competition” from Campus Alberta (CAN). The CAN “Entrepeneuro” Program is a 7-week cohort-based program designed to support early-stage neuroscience projects to launch or grow their innovations. The prize money awarded will help Zymedyne with patenting costs associated with developing our novel non-opioid-based pain therapeutics platform. To learn more about the CAN Entrepreneuro program, visit: https://www.albertaneuro.ca/entrepreneuro/
Zymedyne – University of Calgary collaboration receives major AICE funding award from Alberta Innovates
Zymedyne Therapeutics is pleased to announce that a 3 year $600,000 AICE Concepts grant from Alberta Innovates has been secured to support critical research at the University of Calgary in support of our drug development program. AICE (Accelerating Innovations into CarE) grants are designed to enable and accelerate early-stage innovators from ideation to conceptualizing across the four domains of commercialization. Alberta Innovates is a provincial organization that “expands the horizon of possibilities to solve today’s challenges and create a healthier and more prosperous future for Alberta and the world.” Current AICE Projects (Including Zymedyne): https://albertainnovates.ca/current-aice-projects/ Learn more more about AICE here: Alberta Innovates on Twitter: https://twitter.com/ABInnovates
Congratulations to Zymedyne’s Chief Science Officer & Co-Founder, Dr. Gerald Zamponi for his long standing contributions to pain research and management! Link to the 2021 ASM Keynote: https://www.canadianpainsociety.ca/2021-ASM Source: @CanadianPain on Twitter
Zymedyne Therapeutics is pleased to announce it has been awarded a UCEED Opportunity Fund Award from University of Calgary. Implemented by Innovate Calgary, the university’s knowledge transfer and business incubator, UCEED serves to support U of Calgary-based child and health enterprises and help commercialize new technologies and accelerate U Calgary start-up companies. Link to the UCEED Opportunity Fund Award Here
Zymedyne is very proud to congratulate Co-founder Dr. Gerald Zamponi on being inducted as Fellow of the 2020 class of National Academy of Inventors (#NAIFellow). Dr. Zamponi is being recognized for his innovation and research in developing and patenting treatments for chronic pain and epilepsy. Only two other Canadian academics out of a total of 175 inductees made the 2020 NAI list. Dr Zamponi will receive his award at the NAI Tenth Annual Meeting, June 8, 2021, in Tampa, Florida. Links: https://academyofinventors.org/ https://academyofinventors.org/wp-content/uploads/2020/12/2020-Fellows-Congratulatory.pdf